In addition, inhibiting the expression of CPT1A in prostate cancer, nasopharyngeal carcinoma, breast cancer, or lung adenocarcinoma cells can increase the sensitivity of cancer cells to hormone-blocking chemotherapy or radiotherapy [58–62]. Here, CPT1A is linked to prostate cancer.